New ELISA eliminates 24 hour incubation by providing pre-coated microplates, enabling results in under 3 hours

ST. PAUL, Minn.–MD Biosciences, a global biotechnology company focused in inflammations and neurology research, announces the recent launch of its new Human Type I Collagen (CI) ELISA, Catalog # M036007, for use with cell culture supernates. The ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for an overnight incubation found with other commercially available kits. Results are achieved in under 3 hours and are sensitive, accurate and reproducible.

Human Collagen Type I ELISA Kit specifications:

100 uL sample size

Dynamic range of 0.062 – 5 ug/mL

Sensitivity < 0.35 ug/mL Rapid < 3 hours Cross-reactivity is < 0.1% with Type II and Type IV collagen Collagen Type I (COL1A1, COL1A2) is the most abundant protein and is found in the skin, connective tissue, tendons, ligaments, cornea, intevertebral disks, scar tissue, and lung. It has been found to be involved in many human diseases such as fibrosis, osteoporosis, cancer and artherosclerosis. It is a fibrillar collagen comprised of 3 polypeptide chains (alpha-chains), which form a unique helical structure. It is a heterotrimer of two á1(I) and one á2(I) chains. Collagen Type I molecules form cross-striated fibrils in the extracellular space, giving the tissues their mechanical strength and providing the major biomechanical scaffold for cell attachment and anchorage of macromolecules. The addition of the Human Collagen Type I assay enhances the line of collagen-related products offered by MD Biosciences, which include Collagen Type II ELISA; Collagen Antibody ELISAs; Bovine and Chicken Collagen Type II, and ArthritoMab Anti-Collagen Antibody Cocktail. About MD Biosciences MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster. The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.